SCHEMBL8063643

SCHEMBL8063643

CCOC(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)C1(NC(=O)OC(C)(C)C)CCCC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTRA1 Q92743 1/20 0.46
CACNA1B Q00975 2/20 0.45
MMP1 P03956 4/20 0.44
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
FAAH O00519 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
KLK5 Q9Y337 1/20 0.41
ALDH1A1 P00352 1/20 0.40
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
EPHX2 P34913 1/20 0.39
ITGB1 P05556 1/20 0.39
ITGA4 P13612 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7229743 0.90 CTSS (0.47) KLK5CTSSCTSK
SCHEMBL7221973 0.87 HTRA1 (0.40) HTRA1KLK5ITGB3ITGA2BCTSL
SCHEMBL8067917 0.85 NPSR1 (0.54) KLK5ALDH1A1CTSSCTSK
SCHEMBL16462455 0.85 CACNA1B (0.50) CACNA1BKLK5ALDH1A1ITGB3ITGA2B
SCHEMBL17106960 0.85 CACNA1B (0.50) CACNA1BKLK5ALDH1A1ITGB3ITGA2B
SCHEMBL3149446 0.84 PPARG (0.54) CACNA1BPPARGPPARAKLK5ALDH1A1
SCHEMBL31461540 0.84 PPARG (0.44) HTRA1CACNA1BMMP1PPARGPPARA
SCHEMBL7223168 0.84 KLK5 (0.45) KLK5ALDH1A1CTSLCTSBCTSS
SCHEMBL7229912 0.83 HDAC1 (0.47) CTSSCTSK
SCHEMBL6376830 0.83 ECE1 (0.42) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0655461-B1 Cyclic amino acid derivatives having ACE and NEP inhibiting activity NOVARTIS AG (CH) 2000-06-07 EP disclosed
US-5668158-A TREATMENT OF CARDIOVASCULAR DISORDERS NOVARTIS CORPORATION (US) 1997-09-16 US disclosed
US-5506244-A TREATING CARDIOVASCULAR DISORDERS CIBA-GEIGY CORPORATION (US) 1996-04-09 US disclosed
EP-0655461-A1 Cyclic amino acid derivatives having ACE and NEP inhibiting activity CIBA-GEIGY AG (CH) 1995-05-31 EP disclosed